NCT04320238

Experimental Trial of rhIFNα Nasal Drops to Prevent 2019-nCOV in Medical Staff

An Clinic Trial of Recombinant Human Interferon Alpha Nasal Drops to Prevent Coronavirus Disease 2019 in Medical Staff in Epidemic Area

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 2,944 (estimated)
• Sponsor: Shanghai Jiao Tong University School of Medicine · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The investigators plan to carry out an experimental study on the preventive effect of recombinant human interferon alpha nasal drops on the infection of 2019 new coronavirus in medical staff.

Detailed description

The investigators plan to carry out an experimental study enrolling more than 2000 medical staff and divide participants into low-risk group and high-risk group according to whether they can directly exposed to 2019-nCOV infected patients. In the low-risk group, participants will be given recombinant human interferon alpha-1b nasal drops (2-3 drops/nostril/ time, 4 times/ day), and in the high-risk group will be given preventive intervention with interferon nasal drops and thymosin-α (thymosin was injected subcutaneously once / week), and the intervention time is 28 days.

Conditions

• 2019 Novel Coronavirus Infection

Interventions

Type	Name	Description
DRUG	recombinant human interferon Alpha-1b	recombinant human interferon Alpha-1b nasal drops, 2-3 drops for each nostril per time, 4 times per day.
DRUG	thymosin alpha 1	thymosin alpha 1 subcutaneous injection 1 time per week.

Timeline

• Start date: 2020-01-21
• Primary completion: 2020-05-01
• Completion: 2020-06-01
• First posted: 2020-03-24
• Last updated: 2020-03-31

Locations

1 site across 1 country: China